Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05188638
Other study ID # SIS-01
Secondary ID 2020-004462-19
Status Completed
Phase Phase 1
First received
Last updated
Start date October 8, 2021
Est. completion date April 13, 2022

Study information

Verified date April 2022
Source SoftOx Solutions AS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: This first-in-human study will investigate the safety and tolerability of single and multiple doses of nebulised SoftOx Inhalation Solution (SIS) delivered via a jet nebuliser to healthy subjects. Objectives: The objective of the current study is to assess the safety and tolerability of single and multiple ascending doses of nebulised SIS in healthy subjects. Eligibility: Subjects are eligible to participate in this study if they are healthy, between 18 and 55 years of age, and have a Body Mass Index (BMI) of ≥ 18.5 and ≤ 29.9 kg/m2. Subjects are not eligible to participate in this study if they have recently participated in another clinical trial or have donated blood, have a medical condition or a history of drug hypersensitivity, are using concomitant medication, or have a positive drugs of abuse test. Design: A randomised, double-blind, and placebo-controlled trial. Subjects will be enrolled into one of three single dose groups or into one of four multiple dose groups. The two first multiple dose groups will be dosed once daily (OD) for five days. The two last multiple dose groups will be dosed twice daily (BID) for four days plus a morning dose on Day 5, or four times daily (QID) for four days plus a morning dose on Day 5, respectively. The investigational medicinal product (SIS or placebo; IMP) will be delivered via a jet nebuliser and inhaled through a mask over a period of up to 15 minutes. Each treatment group will comprise eight subjects who will be randomised to receive SIS or placebo in a 3:1 ratio. A Safety Monitoring Committee (SMC) will review the safety and tolerability data from all preceding groups and decide whether the planned next dose regimen is acceptable prior to initiating the dosing in a new dose group. The dose to be administered in the multiple dose groups will depend on the results obtained in the single dose groups and will be decided by the SMC. The dose tested in the first multiple dose group will be the second highest well-tolerated single dose or lower.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date April 13, 2022
Est. primary completion date April 13, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Has signed a written informed consent. 2. Is 18 to 55 years of age (both inclusive). Women of child-bearing potential must be sexually abstinent or should agree to use effective contraceptive methods3 throughout the course of the study. 3. Has a Body Mass Index (BMI) of 18.5-29.9 kg/m2 (both inclusive). 4. Good health in the opinion of the Investigator based upon medical history, physical examination, vital signs, oxygen saturation, electrocardiogram (ECG), lung function, and laboratory profile of blood and urine. 5. Is able to comply with the inhalation procedure of inhaling through the nose and exhaling through the mouth, in the opinion of the Investigator. 6. Has negative urine drug screen and negative alcohol breath test on the day of screening and before the (first) administration of IMP. Exclusion Criteria: 1. Any surgical or medical condition, including findings in the medical history or in the pre-study assessments, or any other significant disease, that in the opinion of the Investigator, constitutes a risk or a contraindication for the participation of the subject in the study or that could interfere with the study objectives, conduct, or evaluation. 2. Has had cancer within the last 10 years except for adequately managed basal cell carcinoma and squamous cell carcinoma of the skin. 3. Intake of any prescription or non-prescription medication, or herbal products with known pharmacological effects (e.g., St. John's wort), within 2 weeks or 5 half-lives of the drug, whichever is longer, before the (first) administration of IMP with the exception of paracetamol, which is allowed up to 1000 mg QID dosed according to labelling as well as hormonal contraceptives and hormonal replacement therapy. 4. Participation in the treatment phase of a clinical trial with an investigational new drug within one month before the (first) administration of IMP. 5. Is a smoker or has used any form of nicotine product including e-cigarette, snuff, chewing tobacco, nicotine gum, etc., on a regular basis within three months before the (first) administration of IMP. 6. Has a history (within the last two years) or is at present an abuser of alcohol or narcotics, or is a user of recreational drugs (e.g., cocaine). 7. Has donated or lost > 400 mL blood within one month before the (first) administration of IMP. 8. Has previously been randomised in this study. 9. Is pregnant or lactating at screening or time of the (first) administration of IMP. 10. Ascertained or presumptive allergy/hypersensitivity to SIS; history of anaphylaxis to drugs or serious allergic reactions leading to hospitalization or any other allergy reaction in general, which the Investigator considers may affect the safety of the subject and/or outcome of the study. 11. Inability to communicate or cooperate with the Investigator (e.g., language problem, illiteracy, poor mental status) or to comply with the requirements of the study. 12. Legal incapacity or limited legal capacity. 13. Is considered by the Investigator, unsuitable to participate in the study for any other reason.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SoftOx Inhaled Solution (SIS)
SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
Placebo
Sterile isotonic saline

Locations

Country Name City State
Denmark DanTrials ApS Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
SoftOx Solutions AS

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of adverse events (AEs). From the start of the first administration of IMP to 2 or 3 days after the last administration of IMP
Primary Severity of adverse events (AEs). From the start of the first administration of IMP to 2 or 3 days after the last administration of IMP
Primary Change from baseline in forced expiratory volume in 1 second (FEV1) From 30 minutes after the start of the first administration of IMP to 2 or 3 days after the last administration of IMP
Primary Change from baseline in oxygen saturation measured by pulse oximetry From the start of the first administration of IMP to 2 or 3 days after the last administration of IMP
Primary Change from baseline in local tolerability Subjects will be asked to complete a brief questionnaire regarding symptoms (irritation, burning sensation/pain, coughing, sneezing, or other) from the mouth, nose, and respiratory tract. Immediately after completion of the inhalation to 2 or 3 days after the last administration of IMP
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1